SCHEMBL16631413

SCHEMBL16631413

Cc1cc(C)c2cc(C)c(=O)nc-2[nH]1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.35
MAPK1 P28482 1/20 0.35
FGFR1 P11362 1/20 0.34
FGFR2 P21802 1/20 0.34
CA1 P00915 1/20 0.33
KDM4E B2RXH2 5/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
ATM Q13315 1/20 0.33
ERAP1 Q9NZ08 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
GAA P10253 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
LPO P22079 1/20 0.31
PTGS1 P23219 1/20 0.31
ADORA1 P30542 2/20 0.31
ALDH1A1 P00352 2/20 0.31
ADORA2A P29274 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16631550 0.85 AMY1A (0.35) MAPTCA1KDM4EHPGDHSD17B10
SCHEMBL18081781 0.81 FGFR1 (0.33) FGFR1FGFR2KDM4EHPGDHSD17B10
SCHEMBL18080465 0.81 L3MBTL1 (0.35) MAPTMAPK1FGFR1FGFR2L3MBTL1
SCHEMBL16631382 0.78 NOTUM (0.36) KDM4EHPGDHSD17B10ALDH1A1HTT
SCHEMBL18081939 0.76 NPC1 (0.32) FGFR1FGFR2KDM4EHPGDHSD17B10
SCHEMBL16631385 0.74 AMY1A (0.35) FGFR1FGFR2KDM4EHPGDHSD17B10
SCHEMBL18081954 0.73 NPC1 (0.33) KDM4EHPGDHSD17B10NPC1RAB9A
SCHEMBL16631434 0.73 MGAM (0.33) KDM4EHPGDHSD17B10NPC1RAB9A
SCHEMBL16631535 0.72 NPC1 (0.35) FGFR1FGFR2KDM4EHPGDHSD17B10
SCHEMBL18081932 0.72 MAPK1 (0.40) MAPTMAPK1KDM4EHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 MAPT 3290/4885MAPK1 4185/4885FGFR1 4176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.